Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock

DaVita HealthCare (DVA), a prominent U.S. dialysis service provider, is identified by Zacks as a strong momentum stock, despite its #3 (Hold) rank. The company exhibits robust technical indicators, including an 'A' VGM Score and 'B' Momentum Style Score, with shares appreciating 2.7% over the past four weeks. Furthermore, an analyst recently revised fiscal year 2025 earnings estimates upwards, with the Zacks Consensus Estimate at $10.76 per share, and DVA boasts a historical average earnings surprise of +3.6%, making it a notable consideration for investors.

Analysis

DaVita Inc. (DVA) presents a mixed but noteworthy profile, characterized by strong momentum indicators juxtaposed with a neutral analyst consensus rating. According to Zacks' proprietary scoring, DVA earns a top-tier 'A' for its overall VGM (Value, Growth, Momentum) score and a 'B' for Momentum, supported by a 2.7% share price increase over the past four weeks. This suggests positive near-term technical strength. On the earnings front, the company has a track record of delivering positive results, boasting an average earnings surprise of +3.6%. While one analyst has recently revised their fiscal 2025 earnings estimate upwards, the Zacks Consensus Estimate has remained unchanged at $10.76 per share, indicating this optimism is not yet widespread. This lack of broad upward revision is reflected in the stock's overall Zacks Rank of #3 (Hold), signaling that despite the positive momentum factors, the broader analyst outlook remains neutral.

Key Decisions for Investors

• Investors with a momentum-driven strategy should note DVA's positive technical signals, including its 'B' Momentum Score and recent price appreciation, but weigh this against the neutral Zacks #3 'Hold' rank.
• Consider the company's consistent operational performance, evidenced by an average earnings surprise of +3.6%, as a potential sign of fundamental stability.
• Before making a decision, monitor for further analyst revisions to the FY2025 earnings estimate, as the current consensus of $10.76 per share has not yet moved despite a recent singular upward revision, suggesting the broader outlook is still cautious.